Comparison To Peers: Bausch Health Companies Inc. (BHC), TherapeuticsMD Inc. (TXMD)

You should consider shares of Bausch Health Companies Inc. (NYSE:BHC) and TherapeuticsMD Inc. (NASDAQ:TXMD) if you are looking for a great stocks to invest in. Starting with the BHC shares, which traded at $28.27 at the close of the recent session, dropping -0.95%. On Tuesday, the company’s shares shed -$0.27 from its value which represented in intraday trading. The stock is now 16.10% higher in year-to-date (YTD) trading. BHC’s intraday high was $28.315 while its lowest price touched $27.70. The stock’s 52-week high price is $28.79, which means the current price is at -1.81%. In terms of trading activity, the daily trading volume fell to 3049939 against 200-day average trading volume of 3,744,618 shares.

What are analyst forecasts for Bausch Health Companies Inc. (NYSE:BHC)?

At a consensus rating of 4.33, BHC is trending as a streaking Moderate Buy, as it has been the case a month ago when 15 analysts called it a Moderate Buy. Two months ago, 15 analysts recommended, on average, that BHC stock is a Moderate Buy. The Healthcare company’s shares’ overall bearish trend saw it close higher on Tuesday compared to its opening price of $28.03 on the day.

Forecasts for Bausch Health Companies Inc. (NYSE:BHC) give the stock a fair value for the growth of 7.31% from its last price. The 12-month price forecast for the stock by analysts puts the stock’s mean price target at $30.50, which means the price per share could rise by nearly $2.23. The price range target is between a low of $9.00 and a high of $60.00. The stock would need to gain by about $52.88 to hit the estimated high or 0.61% from its 12-month low.

The consensus among 18 analysts is that it is a good time for one to Overweight in the Bausch Health Companies Inc. 10 analysts rate BHC as a Buy, with 1 of 18 analysts rate it as a Sell. 0 have valued the stock as Overweight and 6 have recommended that investors Hold.

Bausch Health Companies Inc. (NYSE:BHC) Upgrades and Downgrades

In terms of rating changes, Goldman on December 02, 2019, Initiated Bausch Health Companies Inc. (BHC) at Neutral. Analysts at Cowen have assigned a Outperform rating for the stock in their research note on October 25, 2019 with an estimated price target of $35. Moreover, Guggenheim analysts issued a rating of Buy for the stock on September 12, 2019. On August 15, 2019, the stock earned a Buy rating due to an analyst call from TD Securities, while analysts from Wolfe Research on July 19, 2019 suggested that the stock is Outperform.

TherapeuticsMD Inc. (NASDAQ:TXMD) adds -$0.06 on Tuesday

The TXMD stock has tanked -38.06% year-to-date and is currently trading at $2.36, which is -61.25% below its 52-week high. The company shares lost -2.48% on the day and have risen nearly 29.67% off a low hit. At current levels, TherapeuticsMD Inc. has a valuation of about $38.80M. As of 12/03/19, this stock has fallen -8.17% during the week and closed at $2.42 in the previous session. However, recent TherapeuticsMD Inc. stock performance shows that TXMD shares are -17.48% down over the last month, and -15.41% down for the last three months.

Earnings per share (EPS) estimates for the current quarter are -$0.17, with the trailing 12-month share earnings at -$0.69. The ratio is expected to be down by -23.70% for the current year 2019 and 30.10% for next year. Over the next 5-year period, earnings per share will be 19.50%. But will the TXMD stock surprise in the current quarter results, where the -$0.13 actual EPS reported on 9/29/2019 surprised by 31.60% or was higher by $0.06 from the estimated -$0.19.

Sales Growth to climb 169.70% for the year

How well will TherapeuticsMD Inc. perform as a business over the current quarter, year and next 5-year period? Compared to the year-ago quarter, analysts forecast the company to bring in between $10.7M and $13.8M in current quarter sales. The consensus estimated for the current quarter is $12.88M from sales. Forecasts for this fiscal year are between $30.4M and $47.5M and the consensus estimate for sales is at $42.97M. TXMD has its next quarter sales estimates at between $20.5M and $20.5M, with the quarter-over-quarter growth estimates at 419.40% and the annual growth forecast for the year at 169.70%.

Who owns shares in TherapeuticsMD Inc. (TXMD)?

Let’s briefly focus on the share ownership of the TherapeuticsMD Inc. (NASDAQ:TXMD) stock, where we find that 78.61% of shares are held by institutions. JP Morgan Chase & Company tops the list of institutional owners as it is holding 19.91 million shares or 7.34% of shares outstanding. FMR, LLC and Blackrock Inc. held 18.62 million and 16.52 million representing 6.87% and 6.09% respectively at the close of the last trading session. As of Sep 29, 2019, Bank Of New York Mellon Corporation accounted for 15.49 million shares at over 56.21 million. This represented 5.71% of shares outstanding. Price (T.Rowe) Associates Inc held 15.3 million shares at over 55.55 million representing 5.64% of shares outstanding.

TXMD Insider Activity

On 12/04/2018, President & Secretary by the name Milligan John C K Iv sold 129000.0 shares worth $642400.0 at the price of $4.98 per share. Filings also show that Milligan John C K Iv sold a total of 129000.0 shares on 12/06/2018 valued at $589500.0. Since the last insider activity, the company’s share price has dropped -47.73%.